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Abstract
Background: In order to carry out a methodological research survey of systematic reviews of
adverse effects we needed to retrieve a sample of systematic reviews in which the primary
outcome is an adverse effect or effects.
Methods: We carried out searches of the Database of Abstracts of Reviews of Effects (DARE) and
the Cochrane Database of Systematic Reviews (CDSR) for systematic reviews of adverse effects
published between 1994 to 2005. The search strategies used a combination of text words in the
title and abstract, Medical Subject Headings (MeSH) and subheadings/qualifiers. In addition, DARE
records in progress were hand searched. No language restrictions were placed on any of the
searches. The performance, in terms of sensitivity and precision, of the search strategies and their
combinations were tested in DARE and CDSR.
Results: In total 3635 records were screened of which 257 met our inclusion criteria. The
precision of the searches in CDSR was low (0% to 3%), and no one search strategy could retrieve
all the relevant records in either DARE or CDSR. Hand searching the records from DARE and
CDSR not retrieved by our searches indicated that we had missed relevant systematic reviews in
both DARE and CDSR. The sensitivities of many of the search combinations were comparable to
those found when searching for primary studies in which adverse effects are secondary outcomes.
Conclusion: Searching major databases of systematic reviews, for systematic reviews of adverse
effects, proved more difficult than anticipated due to a lack of standard terminology used by the
authors, inadequate indexing and the variations in the search interfaces of the databases. At present
hand searching all records in DARE and CDSR seems to be the only way to ensure retrieval of all
systematic reviews of adverse effects in these databases.
Background
Balanced decision making in health care requires evidence
on the potential adverse effects of interventions as well as
their beneficial effects. Although well-conducted system-
atic reviews of adverse effects are important sources of evi-
dence such reviews are relatively rare in the literature [1]
and it is not clear whether the process of identifying rele-
vant reviews may resemble the proverbial "looking for a
needle in the haystack". Indeed, poor indexing and incon-
sistent terminology have hampered efforts to identify
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studies that report original data on adverse effects [2-5].
These primary studies often do not consider adverse
effects as the main outcome and, therefore, may not con-
tain this information in their title or abstract or be indexed
with terms for adverse effects.
It should be easier to identify systematic reviews that were
conducted with the express purpose of evaluating adverse
effects. We might expect that study retrieval would be
facilitated by some mention of adverse effects in the title,
abstract or indexing terms. As part of a wider study of
methods used in systematic reviews of adverse effects we
decided to assess whether we could identify systematic
reviews of adverse effects quickly and easily in two major
databases of systematic reviews.
Methods
We searched for systematic reviews of adverse effects using
the Database of Abstracts of Reviews of Effects (DARE)
and the Cochrane Database of Systematic Reviews
(CDSR). These databases were chosen because they are
major collections of systematic reviews. No additional
sources were searched as DARE is compiled through rigor-
ous monthly searches of bibliographic databases (includ-
ing MEDLINE and EMBASE) as well as hand searching key
journals, grey literature, and regular searches of the web
[6]. No language restrictions were placed on the searches
and the searches aimed to retrieve systematic reviews pub-
lished from 1994 onwards.
Database of Abstracts of Reviews of Effects (DARE)
Three approaches were used to identify records in DARE
(figure 1). Firstly, text word searches for synonyms of
'adverse effects' and related terms were carried out in the
record title and abstract. These terms were selected from
previous research [4]. Each DARE abstract contains a sum-
mary of a systematic review including a critical commen-
tary. It was found that searching the full abstracts of DARE
records would have identified many irrelevant records as
these abstracts contain phrases such as; 'no information
on the incidence of adverse reactions are included', 'it
would have been appropriate to include mention of
adverse events' or 'the adverse effects of the treatment
were not assessed in the review'. The searches of the DARE
abstracts were, therefore, restricted to the 'outcomes
assessed in the review' field as the primary outcome of a
review is described in this field [7].
The second approach was to use Medical Subject Head-
ings (MeSH), such as DRUG TOXICITY, and subheadings/
qualifiers unattached to any indexing terms ('floating'
subheadings), such as 'adverse effects'. This was an essen-
tial part of the search strategy as many systematic reviews
examine specific adverse effects, such as, headaches, so
would not necessarily be identified by text words of syno-
nyms of 'adverse effects' and searching for each named
potential adverse effect individually would be impractical.
Previous research has also indicated the usefulness of
searching with 'floating' adverse effect subheadings [2-4].
Finally, DARE records in the process of being written do
not yet have an 'outcomes assessed in the review' field.
The titles of all of these 'provisional' records were, there-
fore, hand searched by the researchers to identify addi-
tional relevant reviews.
To enable all three approaches to be executed, three
searches of DARE were conducted, two via the Centre for
Reviews and Dissemination (CRD) website and one via
The Cochrane Library website (figure 1). The text word
search was conducted using the CRD website because this
interface allows searches to be limited to sections of the
structured abstracts, such as, the 'outcomes assessed in the
review' field, whereas The Cochrane Library interface does
not. The provisional abstracts were scanned via the CRD
website as this contains the most up to date set of provi-
sional DARE records. Another search was conducted using
The Cochrane Library because its interface allows searches
of 'floating' subheadings to be conducted whereas the
CRD website does not.
The Cochrane Database of Systematic Reviews (CDSR)
Searches for Cochrane Reviews were conducted in the web
version of The Cochrane Library (Issue 1: 2005) (figure 2).
These searches used text words in the title and abstract,
MeSH terms, and 'floating' subheadings. As with DARE
records many irrelevant records would have been
retrieved if the full CDSR structured abstracts had been
searched. The 'objectives' section of a CDSR abstract out-
lines the primary outcome of a review [8]. As searches in
CDSR cannot be limited to sections of the abstract text
words were searched for in the abstract using the proxim-
ity operator to limit to within 20 words of the term 'objec-
tives' (figure 2).
Inclusion criteria
The results from all four searches were then entered into
an Endnote Library and duplicate records were removed.
Two researchers independently screened the titles and
abstracts and selected records for inclusion in the study. A
review was included if the primary outcome was an
adverse effect or effects, that were known to be, or sus-
pected of being, associated with the intervention. This was
regardless of whether the review indicated that the inter-
vention increased or reduced the outcome.
It was suspected that relevant reviews had been missed by
the searches so those records not retrieved by the search
strategies in CDSR (n = 887) and DARE (n = 2646) were
also scanned for relevant systematic reviews. All relevantBMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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Search strategies for retrieving systematic reviews of adverse effects from DARE Figure 1
Search strategies for retrieving systematic reviews of adverse effects from DARE.
Search Approach 1: Searching with text words in the title and abstract 
DARE searched via CRD website at http://www.york.ac.uk/inst/crd/ 
Searched: 31/03/05 
(safe or safety or adverse or tolerability or toxicity or toxic or adrs or adr or tolerance 
or tolerate or harm or harms or harmful or complication$ or risk or risks)/xoa OR 
side(w)effect$/xoa OR undesirable(w)effect$/xoa OR  
treatment(w)emergent/xoa OR  
(safe or safety or adverse or tolerability or toxicity or toxic or adrs or adr or tolerance 
or tolerate or harm or harms or harmful or complication$ or risk or risks)/ttl OR 
side(w)effect$/ttl OR undesirable(w)effect$/ttl OR 
treatment(w)emergent/ttl 
Key 
/xoa – restricts the search to the ‘outcomes assessed in the review’ field 
/ttl – restricts the search to the ‘title’ field 
$ - truncation symbol 
(w) – words must be adjacent to each other 
Search Approach 2: Searching using indexing terms
DARE searched via the Cochrane Library at 
http://www.nelh.nhs.uk/cochrane.asp 
Issue 1 2005 
Searched: 31/03/05 
#1 Any MeSH descriptor with qualifier: AE  
#2 Any MeSH descriptor with qualifier: DE  
#3 Any MeSH descriptor with qualifier: CO  
#4 Any MeSH descriptor with qualifier: PO  
#5 Any MeSH descriptor with qualifier: TO  
#6 Any MeSH descriptor with qualifier: CI  
#7 MeSH descriptor Drug Hypersensitivity explode all trees  
#8 MeSH descriptor Drug Toxicity explode all trees  
#9 MeSH descriptor Product Surveillance, Postmarketing explode all trees  
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 
Key 
Sets #1 to #6 are ‘floating’ subheadings 
Search Approach 3: Searching ‘provisional’ abstracts 
All records in progress, ‘provisional’ abstracts, were scanned for relevant reviews of 
adverse effects. BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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Search strategies for retrieving systematic reviews of adverse effects from CDSR Figure 2
Search strategies for retrieving systematic reviews of adverse effects from CDSR.
Cochrane Database of Systematic Reviews (CDSR) searched via The Cochrane 
Library at http://www.nelh.nhs.uk/cochrane.asp 
Issue 1 2005 
Searched: 31/03/05 
#1 Any MeSH descriptor with qualifier: AE  
#2 Any MeSH descriptor with qualifier: DE  
#3 Any MeSH descriptor with qualifier: CO  
#4 Any MeSH descriptor with qualifier: PO  
#5 Any MeSH descriptor with qualifier: TO  
#6 Any MeSH descriptor with qualifier: CI  
#7 MeSH descriptor Drug Hypersensitivity explode all trees  
#8 MeSH descriptor Drug Toxicity explode all trees  
#9 MeSH descriptor Product Surveillance, Postmarketing explode all trees  
#10 (safe or safety or adverse or tolerability or toxicity or toxic or adrs or adr or 
tolerance or tolerate or harm or harms or harmful or complication* or risk or risks) 
near/20 objective* in Abstract  
#11 (side next effect*) near/20 objective* in Abstract  
#12 (undesirable next effect*) near/20 objective* in Abstract 
#13 (treatment next emergent) near/20 objective* in Abstract 
#14 (safe or safety or adverse or tolerability or toxicity or toxic or adrs or adr or 
tolerance or tolerate or harm or harms or harmful or complication* or risk or risks) in 
Record Title  
#15 (side next effect*) in Record Title  
#16 (undesirable next effect*) in Record Title  
#17 (treatment next emergent) in Record Title  
#18 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or 
#14 or #15 or #16 or #17  
Key 
Sets #1 to #6 are ‘floating’ subheadings 
next – words must be adjacent to each other 
near/20 – words must be within 20 words of each other in either direction BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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records identified then formed our gold standard (GS) set
of records.
Assessing the performance of the search strategies
Once we had established our gold standard set of records
we were able to test the performance of individual
approaches in retrieving the gold standard records. The
search terms used to identify the systematic reviews were
assessed for their usefulness in retrieving relevant records
by measuring their sensitivity and precision. Sensitivity is
a measure of the search's ability to identify relevant
papers, and a high value is important for searches for sys-
tematic reviews. Precision, on the other hand, is a measure
of the proportion of relevant records identified by a search
strategy expressed as a percentage of all articles (relevant
and irrelevant) identified by that strategy. Highly sensitive
strategies tend to have low levels of precision. Sensitivity
and precision for each database were calculated as fol-
lows;
Results
In total 4262 records were retrieved from CDSR and
DARE, of which 3635 were unique records. From the 3635
titles and abstracts screened, 298 full reports were
retrieved and 256 reviews (257 publications) met our
inclusion criteria. Of the 257 publications, 246 had DARE
abstracts and 11 were Cochrane Reviews (figure 3).
The hand search of the records in CDSR and DARE not
retrieved by our search strategies identified 13 additional
records (10 from DARE and 3 from CDSR) which met our
inclusion criteria. In total, therefore, 270 systematic
Sensitivity
number of GS records retrieved
number of GS rec
=
o ords indexed
in the database under investigation
×100
Precision
number of GS records retrieved
total number of re
=
c cords retrieved
×100
Summary of systematic review identification, retrieval and inclusion/exclusion Figure 3
Summary of systematic review identification, retrieval and inclusion/exclusion.
Title and abstracts identified  
and screened, n = 3635 
Full copies ordered and received, n=298 
Excluded, n=41 
Prevention of adverse effect, n =1 
Adverse effect is secondary outcome, n=18 
Methodology paper, n=1 
Treatment of adverse effect, n = 3 
Clinical effectiveness, n=16 
Drop out/ Discontinuation rates, n = 1 
Overdose, n = 1 
Publications meeting the inclusion criteria  
and included in the review, n = 257 
Total number of Cochrane systematic reviews, n = 11 
Total number of DARE systematic reviews, n =246 BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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reviews of adverse effects were identified; 256 from DARE
and 14 from CDSR.
The relevant records not retrieved by our search strategies
were sifted for any potentially relevant generic adverse
effect search terms. Only 2 of the 13 contained potentially
useful terms. Both contained the MeSH indexing term
RISK FACTORS and one had the term 'hazards' in the title.
These search terms, in addition to the terms used in our
search strategies, were tested to identify the most sensitive
search strategy possible.
The sensitivity and precision of the different search
approaches are presented in table 1. Searching using
'floating' subheadings provided the highest sensitivity in
both DARE (85%) and CDSR (64%) and the precision of
all the search approaches was much higher in DARE (16%
to 71%) than in CDSR (0% to 3%).
Single search terms with the highest precision
All the single search terms in CDSR yielded very low pre-
cision (0 to 3%). In DARE, however, some terms did pro-
vide high precision (table 2). The single terms with the
highest precision were the MeSH terms, Exp PRODUCT
SURVELLIENCE, POSTMARKETING (73%), Exp DRUG
HYPERSENSITIVITY (67%) and Exp DRUG TOXICITY
(67%). However, the sensitivity of searching with each of
these terms was very low (1–3%) (table 2). Searches using
all the chosen synonyms of 'adverse effects' in the title had
a reasonable precision of 29% (table 1). However, some
individual single terms yielded higher precision. For
example, searching with the term 'adverse' in the title gave
65% precision, 'complication$' 50% and 'side effect$'
43%.
Single search terms with the highest sensitivity
The most sensitive search strategy used 'floating' subhead-
ings (table 1). 'Floating' all the subheadings retrieved 85%
of the DARE records and 64% of the Cochrane Reviews.
The most sensitive 'floating' subheadings in DARE were
'adverse-effects' at 77%, followed by 'chemically-induced'
(33%), 'drug-effects' (16%), and 'complications' (14%)
(table 3). In CDSR 'adverse-effects' was again the most
sensitive 'floating' subheading (64%), followed by 'chem-
ically-induced' (29%), and 'drug-effects' (29%).
Most sensitive search strategies
The most sensitive search strategy in DARE, with the terms
tested here, used a combination of text words in the title
and abstract, a MeSH term and 'floating' subheadings (see
figure 4). This strategy retrieved 1,507 records of which
241 were deemed relevant, yielding a sensitivity of 94%
and precision of 16%.
In CDSR the most sensitive search strategy used the 'float-
ing' subheading 'adverse effects' combined with searching
Table 1: Sensitivity and precision of searches in DARE and CDSR
No of Papers Retrieved No of Relevant Papers Sensitivity (%) Precision (%)
DARE (Quasi Gold Standard = 256)
'floating' subheadings: 'adverse effects' OR 'drug effects' OR 
'complications' OR 'poisoning' OR 'toxicity' OR 'chemically 
induced'
1386 217 85% 16%
'floating' subheadings: 'adverse effects' OR 'drug effects' OR 
'complications' OR 'poisoning', 'toxicity' OR 'chemically 
induced' OR Exp DRUG HYPERSENSITIVITY OR Exp DRUG 
TOXICITY OR Exp PRODUCT SURVEILLANCE, 
POSTMARKETING
1386 217 85% 16%
synonyms of 'adverse effects' in the 'title' OR 'outcomes 
assessed in the review' field
873 160 63% 18%
synonyms of 'adverse effects' in the title 462 132 52% 29%
synonyms of 'adverse effects' in 'outcomes assessed in the 
review' field
659 116 45% 18%
exp DRUG HYPERSENSITIVITY OR exp DRUG TOXICITY 
OR exp PRODUCT SURVEILLANCE, POSTMARKETING
14 10 4% 71%
CDSR (Quasi Gold Standard = 14)
'floating' subheadings: 'adverse effects' OR 'drug effects' OR 
'complications' OR 'poisoning', 'toxicity' OR 'chemically 
induced'
416 9 64% 3%
synonyms of 'adverse effects' near/20 objectives in the 'abstract' 
field
1049 5 36% 0.5%
synonyms of 'adverse effects' in the 'title' field 64 2 14% 3%
exp DRUG HYPERSENSITIVITY OR exp DRUG TOXICITY 
OR exp PRODUCT SURVEILLANCE, POSTMARKETING
20 0 % 0 %BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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for 'adverse near/20 objectives' in the abstract. This strat-
egy retrieved 79% (11/14) of the relevant records. How-
ever, the precision of this search was low at 3% (11/338).
Discussion
This research highlights the advantages and disadvantages
of searching databases through the CRD website and The
Cochrane Library website. The CRD website offered the
most current version of DARE and allowed searches to be
limited to sections of the abstract, whereas The Cochrane
Library version of DARE allowed searching using 'floating'
subheadings. Even when conducting consecutive searches
on DARE and CDSR in two different interfaces it is diffi-
cult to retrieve all systematic reviews of adverse effects on
these databases. A sensitive search using text words in the
title and abstract, indexing terms and 'floating' subhead-
ings was unable to retrieve all the records of interest. An
assessment of the missed systematic reviews indicated that
most of these records could not have been retrieved with-
out searching for specific adverse effects. Although adding
these terms to our search strategy would have increased
the sensitivity of the searches, adding the MeSH term RISK
FACTORS, in particular, would have decreased the preci-
sion.
Research has indicated that primary studies of adverse
effects are difficult to locate [2-5]. This has been attributed
to poor reporting, inconsistent terminology and inade-
quate indexing. In primary studies adverse effects are
often not the main outcome of the study and are
described secondary to clinical effectiveness. In this case
study we sought systematic reviews in which the primary
outcome was an adverse effect or effects. It was anticipated
that such studies would be easier to retrieve because
adverse effects would more likely be contained in their
title and abstract and thus their indexing. This was tested
by comparing the sensitivities and precision of our
searches to those reported in earlier research on primary
studies.
Table 3: Single search terms with the highest sensitivity in DARE (Quasi Gold Standard = 256)
Search Term Field Searched No of Papers Retrieved No of Relevant Papers Sensitivity (%) Precision (%)
'adverse-effects' ('floating' subheading) indexing 898 198 77% 22%
'chemically-induced' ('floating' 
subheading)
indexing 201 85 33% 42%
RISK FACTORS indexing 336 69 27% 21%
risk title 140 55 21% 39%
risk outcomes Assessed 168 54 21% 32%
'drug-effects' (floating subheading) indexing 273 42 16% 15%
'complications' (floating subheading) indexing 550 36 14% 7%
adverse outcomes assessed 78 32 13% 41%
safety title 96 29 11% 30%
adverse title 40 26 10% 65%
Table 2: Single search terms with highest precision in DARE (Quasi Gold Standard = 256)
Search Term Field Searched No of Papers Retrieved No of Relevant Papers Precision (%) Sensitivity (%)
exp DRUG HYPERSENSITIVITY indexing 11 8 73% 3%
exp DRUG TOXICITY indexing 3 2 67% 1%
exp PRODUCT SURVEILLANCE, 
POSTMARKETING
indexing 3 2 67% 1%
adverse title 40 26 65% 10%
complication$ title 28 14 50% 5%
side effect$ title 7 3 43% 1%
'toxicity' (floating subheading) indexing 7 3 43% 1%
'chemically-induced' (floating subheading) indexing 201 85 42% 33%
adverse outcomes assessed 78 32 41% 13%
risk title 140 55 39% 21%
side effect$ outcomes assessed 3 1 33% 0%
risk outcomes assessed 168 54 32% 21%
safety title 96 29 30% 11%
complication$ outcomes assessed 46 13 28% 5%
risks outcomes assessed 39 10 26% 4%BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
Page 8 of 11
(page number not for citation purposes)
Interestingly our searches shared similar sensitivities to
those reported by Badgett et al's [2] and Golder et al's [4]
when searching with subheadings and indexing terms
(table 4). The single most sensitive term in all three stud-
ies was the 'floating' subheading 'adverse effects' (table 4).
It is difficult to compare the sensitivities of searching in
the abstract as in this study the searches were limited to
particular sections of the structured abstracts in DARE and
CDSR. Searching the title for synonyms of 'adverse effects'
and related terms showed a higher sensitivity in DARE in
this study than in Badgett et al's [2] and Golder et al's [4].
This may reflect the fact that the relevant studies here con-
tained an adverse effect or effects as their primary out-
come. The lower sensitivity we experienced in CDSR,
however, may reflect the prescribed format of Cochrane
Review titles which focus on the intervention and condi-
tion [8].
Derry et al [3] found that of a sample of randomised con-
trolled trials (RCTs) reporting adverse effects, only 77%
(82/107) could be identified by adverse effects indexing
terms or text words in the title or abstract. In our study,
79% (11/14) of the Cochrane Reviews and 91% (233/
256) of the DARE reviews could be identified by adverse
effects indexing terms or text words in the title or abstract
similar to those used by Derry et al [3]. On further inspec-
tion of the results from Derry et al [3], 53% (53/100) of
their MEDLINE records and 49% (43/88) of their
EMBASE records contained an adverse effect indexing
term compared to 80% (204/256) from DARE in our case
study and 64% (9/14) from CDSR. This indicates that sys-
tematic reviews with a main outcome of an adverse effect
may be marginally easier to retrieve than the RCTs in
MEDLINE and EMBASE examined by Derry et al [3] and
that this may be due in part to indexing. Indexers are
instructed to index only the most important subject mat-
ter in an article [9], therefore, it may not be surprising that
the RCTs in Derry et al's [3] study were not all indexed
with adverse effects terms. It is surprising, however, that so
many of the papers whose primary outcome was an
Most sensitive search strategy to retrieve adverse effects in DARE Figure 4
Most sensitive search strategy to retrieve adverse effects in DARE.
This requires a combination of a search in DARE in both the Cochrane Library and 
the CRD website; 
DARE searched via the Cochrane Library at 
http://www.nelh.nhs.uk/cochrane.asp 
#1 Any MeSH descriptor with qualifier: AE  
#2 Any MeSH descriptor with qualifier: DE  
#3 Any MeSH descriptor with qualifier: CI  
#4 (risk or side effect or complication* or harm or tolerability or safety) in record title 
#5 MeSH descriptor Risk Factors 
#6 #1 or #2 or #3 or #4 or #5 
OR  
DARE searched via CRD website at http://www.york.ac.uk/inst/crd/ 
risk/xoa  
Key  
Sets #1 to #3 are ‘floating’ subheadings 
* - truncation symbol 
/xoa – restricts the search to the ‘outcomes assessed in the review’ field 
Sets #1 to #3 can only be searched in the Cochrane Library interface 
Sets #4 and #5 can be searched in either the Cochrane Library interface or the CRD 
website  
Set 7 can only be searched via the CRD website BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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adverse effect, such as those examined in this study, are
not indexed with adverse effect terms.
The variation in reported sensitivities from the different
case studies may reflect their different inclusion criteria.
Derry et al [3] limited their analysis to RCTs whereas Bad-
gett et al [2] and Golder et al [4] included all types of pri-
mary studies. RCTs in particular, may not have adverse
effects as the main outcome of the study and, therefore,
may not contain this information in the title or abstract.
This in turn means there is less information for an indexer
to identify and index.
Derry et al [3] and Badgett et al [2] did not measure preci-
sion. The precision of the search strategies reported in
Golder et al [4] (0% to 9%) and the precision of the
searches in CDSR in this study (0% to 3%) are similar.
However, the precision of the searches in DARE are higher
in this study. For example, searching with 'floating' sub-
headings gave a precision of 16% in this study compared
with just 3% in Golder et al [4]. Searching for text words
in the title and abstract gave 18% precision in this case
study and 4% in Golder et al [4]. The largest discrepancy
was seen when searching with the MeSH term Exp DRUG
TOXICITY where 67% precision was achieved in this
Table 4: Comparison of search sensitivities in three case studies
Search Terms Sensitivity in 
DARE in this case 
study (GS = 256)
Sensitivity in 
CDSR in this case 
study (GS = 14)
Sensitivity in MEDLINE 
in Badgett et al's study 
[2] (QGS = 323)
Sensitivity in MEDLINE 
in Golder et al's study 
[4] (QGS = 67)
Sensitivity in EMBASE 
in Golder et al's study 
[4] (QGS = 72)
'adverse effects' (floating 
subheading)
77% 64% 86% 79% 79%[1]
'complications' (floating 
subheading)
14% 0% 12% 6% 5%[1]
'poisoning' (floating 
subheading)
0.4% 0% 10% 0% n/a
'chemically induced' (floating 
subheading)
33% 29% Not tested 28% n/a
'toxicity' (floating subheading) 1% 0% Not tested 0% 3%[1]
'drug effects' (floating 
subheading)
16% 29% Not tested 33% n/a
'adverse effects' OR 
'complications' OR 'poisoning' 
(floating subheadings)
79% 57% 95% 82% 81%
'adverse effects OR 
'complications' OR 'poisoning' 
OR 'drug effects' OR 'toxicity' 
OR 'chemically induced' 
(floating subheadings)
85% 64% Not tested 88% 81%[1]
'adverse effects' OR 'drug 
effects' OR 'complications' OR 
'poisoning' OR 'toxicity' OR 
'chemically induced' (all 
floating subheadings) OR exp 
DRUG HYPERSENSITIVITY 
OR exp DRUG TOXICITY 
OR exp PRODUCT 
SURVEILLANCE, 
POSTMARKETING
85% 64% Not tested 88% 81%[1]
exp DRUG 
HYPERSENSITIVITY OR exp 
DRUG TOXICITY OR exp 
PRODUCT SURVEILLANCE, 
POSTMARKETING
4% 0% Not tested 10% 7%
text word 'adverse' in the title 
or abstract
16%[2] 29%[2] 10% 54% 50%
synonyms of 'adverse effects' 
in the title
52% 7% Not tested 18% 19%
synonyms of 'adverse effects' 
in the abstract
45%[2] 36%[2] Not tested 87% 89%
synonyms of 'adverse effects' 
in the title Or abstract
63%[2] 36%[2] Not tested 75% 75%
[1] the subheadings 'adverse drug reaction', drug toxicity' and ' complication' were used in EMBASE as nearest equivalent to 'adverse effects', 
'toxicity' and 'complications'. [2] searches in DARE and CDSR were limited to sections of the structured abstracts.BMC Medical Research Methodology 2006, 6:22 http://www.biomedcentral.com/1471-2288/6/22
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study (although with a very low sensitivity at 1%) com-
pared to a precision of just 8% in Golder et al [4] (and sen-
sitivity of 9%). This higher precision in DARE may reflect
the relative size of DARE and MEDLINE. 5% (256/4919)
of the total number of records on DARE were relevant to
this case study and it would, therefore, not have been pos-
sible to achieve such low precision in DARE as that
achieved by Golder et al [4] in MEDLINE.
Limitations of the study
Our searches were limited to CDSR and DARE. Although
these are excellent sources of systematic reviews of adverse
effects, not all reviews reported as being systematic are
contained in these databases: DARE has a strict quality
inclusion criterion and CDSR contains only Cochrane
Reviews. These databases are sources of systematic reviews
that tend to be of higher methodological quality, which
may reflect better reporting and hence better indexing.
The low number of systematic reviews of adverse effects
on CDSR (14) precluded any useful analysis of the data,
including comparisons to DARE and previous research. In
addition, the usefulness of individual search terms was
difficult to assess because of a low number of records.
The search terms tested in this study were predefined from
previous research and were not obtained by objective
methods [10]. However, the papers (n = 13) not retrieved
by the searches used in this study did not reveal many
additional relevant terms.
Conclusion
Searching major systematic reviews databases for system-
atic reviews of adverse effects proved more difficult than
anticipated due to a lack of standard terminology used by
the authors of reviews, inadequate indexing and the vari-
ations in the search interfaces of these databases.
Our research suggests that it will be even more difficult to
conduct thorough searches for systematic reviews that
report adverse effects as a secondary outcome even in
resources devoted to systematic reviews such as DARE and
CDSR. At present hand searching all records in DARE and
CDSR seems to be the only way to ensure retrieval of all
systematic reviews of adverse effects in these databases.
Key messages
Every systematic review with adverse effect(s) as a primary
outcome should be indexed with appropriate term(s).
Authors of systematic reviews should use standardised ter-
minology to make it explicit that they are reviewing
adverse effects.
Database producers and indexers need to improve the
consistency of their indexing of adverse effects.
The publishers of The Cochrane Library and the producers
of DARE could increase the utility of these databases to
users – the former by allowing searches to be limited to
sections of the structured abstracts in both DARE and
CDSR records, and the latter by introducing the facility to
search DARE with 'floating' subheadings.
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